Combined germline and tumor mutation signature testing identifies new families with NTHL1 tumor syndrome
Data from three FFPE samples of three different NTHL1variant carriers were sequenced on the Illumina NextSeq 500 System, using the Illumina TruSight Oncology 500 (TSO500) kit (Illumina, Inc.) in order to infer the contribution of the COSMIC mutational signatures.